imatinib (Kedem Pharmaceuticals)

N/A

Report date: 2026/01/22 16:42:08

Base Information

Drug Nameimatinib (Kedem Pharmaceuticals)
Drug Alias Nameimatinib
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsPlatelet-derived growth factor receptor inhibitorsSignal transduction pathway inhibitors
TargetsBcr-Abl tyrosine kinasePlatelet-derived growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKedem Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKedem Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A